UY29349A1 - Inhibicion de los objetivos de la hipertensión ocular mediada por arni - Google Patents

Inhibicion de los objetivos de la hipertensión ocular mediada por arni

Info

Publication number
UY29349A1
UY29349A1 UY29349A UY29349A UY29349A1 UY 29349 A1 UY29349 A1 UY 29349A1 UY 29349 A UY29349 A UY 29349A UY 29349 A UY29349 A UY 29349A UY 29349 A1 UY29349 A1 UY 29349A1
Authority
UY
Uruguay
Prior art keywords
ocular hypertension
objectives
arni
inhibition
beta
Prior art date
Application number
UY29349A
Other languages
English (en)
Inventor
Abbot F Clark
Allan R Shepard
Jon E Chatterton
Martin B Wax
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of UY29349A1 publication Critical patent/UY29349A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01007—Acetylcholinesterase (3.1.1.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03009—Na+/K+-exchanging ATPase (3.6.3.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01001—Carbonate dehydratase (4.2.1.1), i.e. carbonic anhydrase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se presenta la interferencia del ARN inhibir la expresión del ARNm del objetivo de la hipertensión ocular a los efectos de reducir la presión intraocular elevada de los pacientes que sufren de glaucoma de ángulo abierto o hipertensión ocular. Los objetivos de la hipertensión ocular incluyen las anhidrasas carbónicasII, IV y XII, los receptores adrenérgicos B(Beta)1 y B(Beta)2, la acetilcolinesterasa, Na+/K+-ATPasa y el cotransportar Na-K-2C1. La hipertensión ocular se trata administrando los ARNi del presente invento.
UY29349A 2005-02-01 2006-01-26 Inhibicion de los objetivos de la hipertensión ocular mediada por arni UY29349A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64892605P 2005-02-01 2005-02-01
US75336405P 2005-12-22 2005-12-22

Publications (1)

Publication Number Publication Date
UY29349A1 true UY29349A1 (es) 2006-05-31

Family

ID=36587258

Family Applications (2)

Application Number Title Priority Date Filing Date
UY29348A UY29348A1 (es) 2005-02-01 2006-01-26 Inhibición de objetivos oculares mediada por arni
UY29349A UY29349A1 (es) 2005-02-01 2006-01-26 Inhibicion de los objetivos de la hipertensión ocular mediada por arni

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY29348A UY29348A1 (es) 2005-02-01 2006-01-26 Inhibición de objetivos oculares mediada por arni

Country Status (14)

Country Link
US (4) US7592324B2 (es)
EP (2) EP1846557A2 (es)
JP (2) JP2008528632A (es)
KR (2) KR20070099048A (es)
AR (2) AR052103A1 (es)
AU (2) AU2006210846A1 (es)
BR (2) BRPI0606979A2 (es)
CA (2) CA2595678A1 (es)
MX (2) MX2007009194A (es)
RU (2) RU2007132848A (es)
SA (1) SA06260487B1 (es)
TW (2) TW200639253A (es)
UY (2) UY29348A1 (es)
WO (2) WO2006083945A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1781787T3 (pl) 2004-08-23 2018-01-31 Sylentis Sau Leczenie zaburzeń oka charakteryzowanych przez podwyższone ciśnienie wewnątrzgałkowe przy użyciu siRNA
AU2006223131A1 (en) 2005-03-11 2006-09-21 Alcon, Inc. RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
GB0505081D0 (en) * 2005-03-14 2005-04-20 Genomica Sau Downregulation of interleukin-12 expression by means of rnai technology
GB0521351D0 (en) * 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
GB0521716D0 (en) * 2005-10-25 2005-11-30 Genomica Sau Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
ATE456053T1 (de) * 2005-12-30 2010-02-15 Ventana Med Syst Inc Na+, k+-atpase-expression bei zervixdysplasie und krebs
CA2659464A1 (en) * 2006-08-24 2008-02-28 Alcon Research, Ltd. Rnai-mediated inhibition of gremlin for treatment of iop-related conditions
WO2008092142A2 (en) * 2007-01-26 2008-07-31 Alcon Research, Ltd. Rnai-mediated inhibition of aquaporin 1 for treatment of ocular neovascularization
WO2008104978A2 (en) * 2007-02-28 2008-09-04 Quark Pharmaceuticals, Inc. Novel sirna structures
EP2192926A1 (en) * 2007-10-01 2010-06-09 Alcon Research, Ltd. Self complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders
JP5646997B2 (ja) * 2007-10-03 2014-12-24 クォーク ファーマシューティカルズ インコーポレーティッドＱｕａｒｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 新規ｓｉＲＮＡ構造
US7973019B1 (en) 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
AR069328A1 (es) 2007-11-15 2010-01-13 Alcon Mfg Ltd Liberacion de rna interferente corto o sirna, intermediada por receptor de lipoproteina de baja densidad
AR069704A1 (es) * 2007-12-18 2010-02-10 Alcon Res Ltd Sistema de administracion de rnai de interferencia y usos del mismo
WO2009090639A2 (en) * 2008-01-15 2009-07-23 Quark Pharmaceuticals, Inc. Sirna compounds and methods of use thereof
CA2738957A1 (en) * 2008-10-22 2010-04-29 Quark Pharmaceuticals, Inc. Methods for treating eye disorders
WO2012161677A1 (en) 2011-05-20 2012-11-29 Alcon Research, Ltd. TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
WO2013103467A1 (en) 2012-01-06 2013-07-11 Alcon Research, Ltd. Interfering rna delivery system and uses thereof
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
IN2015DN02699A (es) 2012-09-05 2015-09-04 Sylentis Sau
US10011837B2 (en) 2014-03-04 2018-07-03 Sylentis Sau SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
EP3429567B1 (en) 2016-03-16 2024-01-10 The J. David Gladstone Institutes Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents
EP3388520A1 (en) * 2017-04-11 2018-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for reducing the expression of nkcc1 in a subject in need thereof
CN109557309B (zh) * 2018-12-04 2021-09-10 九江学院附属医院 碳酸酐酶-2作为检测标记物在肾结石诊断方面的应用
KR102414025B1 (ko) * 2019-06-27 2022-06-29 전북대학교 산학협력단 신규한 에이디피-라이보실 사이클라아제 및 이의 저해제
KR20240014109A (ko) * 2021-05-27 2024-01-31 알닐람 파마슈티칼스 인코포레이티드 탄산 무수화효소 2 발현을 침묵화하기 위한 조성물 및 방법
WO2023239756A1 (en) 2022-06-07 2023-12-14 Generation Bio Co. Lipid nanoparticle compositions and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2361201A1 (en) * 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6326193B1 (en) * 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20050112118A1 (en) * 1999-12-02 2005-05-26 Myriad Genetics, Incorporated Compositions and methods for treating inflammatory disorders
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
JP2003526367A (ja) * 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド Ｒｎａ干渉の方法とｒｎａ干渉組成物
KR20080023768A (ko) * 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
EP1305450A2 (en) * 2000-07-28 2003-05-02 Compugen Inc. Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
CZ302719B6 (cs) * 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
AU2002366641A1 (en) * 2001-12-11 2003-06-23 Fibrogen, Inc. Methods for inhibiting ocular processes
WO2003087840A2 (en) * 2002-04-11 2003-10-23 Oxford Glycosciences (Uk) Ltd Protein involved in cancer
JP2006500910A (ja) * 2002-04-18 2006-01-12 アキュイティ ファーマシューティカルズ、インク． Ｃｎｓと眼の標的遺伝子を特異的に調節するための手段と方法及びその同定法
WO2003093441A2 (en) * 2002-05-03 2003-11-13 Duke University A method of regulating gene expression
WO2004014933A1 (en) * 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
EP1572957A4 (en) * 2002-08-27 2007-10-10 Bristol Myers Squibb Pharma Co IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING THE ACTIVITY OF COMPOUNDS INTERACTING WITH AND / OR MODULATING TYROSINE KINASE PROTEINS AND / OR TYROSINE KINASE PROTEIN PATHWAYS IN MAMMARY CELLS
EP1534832A2 (en) 2002-09-04 2005-06-01 Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin Compositions and methods for tissue specific or inducible inhibition of gene expression
WO2004022750A1 (en) 2002-09-05 2004-03-18 Garvan Institute Of Medical Research Novel diagnostic and therapeutic methods and reagents therefor
US7521431B2 (en) * 2002-11-01 2009-04-21 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of HIF-1 alpha
ATE517992T1 (de) * 2002-11-14 2011-08-15 Dharmacon Inc Funktionelle und hyperfunktionelle sirna
US20040175732A1 (en) * 2002-11-15 2004-09-09 Rana Tariq M. Identification of micrornas and their targets
WO2004072261A2 (en) * 2003-02-11 2004-08-26 Immusol Incorporated Sirna libraries optimized for predetermined protein families
WO2005090606A2 (en) * 2004-01-23 2005-09-29 Dharmacon, Inc. Identification of toxic nucleotide sequences
GB0403600D0 (en) 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease
KR101147147B1 (ko) * 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
CA2576233C (en) * 2004-08-10 2016-03-15 Alnylam Pharmaceuticals, Inc. Conjugate comprising an antagomir and a ligand
PL1781787T3 (pl) * 2004-08-23 2018-01-31 Sylentis Sau Leczenie zaburzeń oka charakteryzowanych przez podwyższone ciśnienie wewnątrzgałkowe przy użyciu siRNA

Also Published As

Publication number Publication date
AU2006210451A1 (en) 2006-08-10
MX2007009194A (es) 2007-09-14
SA06260487B1 (ar) 2011-02-23
RU2007132848A (ru) 2009-03-10
JP2008528632A (ja) 2008-07-31
TW200639252A (en) 2006-11-16
RU2007132874A (ru) 2009-03-10
WO2006084217A2 (en) 2006-08-10
BRPI0606979A2 (pt) 2009-07-28
KR20070099048A (ko) 2007-10-08
WO2006084217A3 (en) 2007-09-13
MX2007009200A (es) 2007-09-14
KR20070099673A (ko) 2007-10-09
JP2008528637A (ja) 2008-07-31
EP1846557A2 (en) 2007-10-24
US20110124708A1 (en) 2011-05-26
TW200639253A (en) 2006-11-16
WO2006083945A8 (en) 2007-10-11
US20090326044A1 (en) 2009-12-31
AR052102A1 (es) 2007-02-28
AR052103A1 (es) 2007-02-28
UY29348A1 (es) 2006-05-31
WO2006083945A3 (en) 2007-08-23
CA2595790A1 (en) 2006-08-10
BRPI0607096A2 (pt) 2009-08-04
AU2006210451B2 (en) 2011-09-22
CA2595678A1 (en) 2006-08-10
EP1848803A2 (en) 2007-10-31
AU2006210846A1 (en) 2006-08-10
WO2006083945A2 (en) 2006-08-10
US20060172965A1 (en) 2006-08-03
US20060172963A1 (en) 2006-08-03
US7592324B2 (en) 2009-09-22

Similar Documents

Publication Publication Date Title
UY29349A1 (es) Inhibicion de los objetivos de la hipertensión ocular mediada por arni
UY30060A1 (es) Inhibición de la rho quinasa mediada por arni para el tratamiento de trastornos
ECSP066855A (es) Derivados de benceno sustituidos por glucopiranosilo, medicamentos que contienen esos compuestos, su aplicación y procedimiento para su preparación
CR10041A (es) Uso de vías inhibitorias coplementarias para el tratamiento de enfermedades oculares
UY30058A1 (es) (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa
CR20120289A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
EA201071413A1 (ru) Способ и композиция для лечения повышения внутриглазного давления и глаукомы
PE20080716A1 (es) Coterapia constituida por un derivado de heterociclosulfamida benzofusionado y uno o varios agentes anticonvulsivantes y/o antilepticos
TW200700070A (en) Enhanced bimatoprost ophthalmic solution
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
AR056852A1 (es) INHIBICIoN DE HIF1A INTERMEDIADO POR RNAI PARA EL TRATAMIENTO DE ANGIOGENESIS OCULAR
UY30254A1 (es) Tratamientos para la alergia ocular
AR066972A1 (es) Derivados azapeptidicos
CY1117458T1 (el) Αγωνιστες αδενοσινης α1 για τη θεραπευτικη αντιμετωπιση του γλαυκωματος και της οφθαλμικης υπερτασης
AR062395A1 (es) Uso de derivados del 2.5-dihidroxibenceno para el tratamiento de enfermedades oculares
AR060222A1 (es) Uso de inhibidores de jun quinasas n- terminales para tratar glaucoma
UY31824A (es) Nuevos compuestos
MX2009001977A (es) Derivados profarmacologicos de aminoacilo y medicamentos para el tratamiento de enfermedades tromboembolicas.
UY31204A1 (es) Derivados de macrolactona
ITMI20070890A1 (it) Composizioni oftalmiche per il trattamento della ipertensione oculare e del glaucoma
AR064015A1 (es) Inhibicion mediada por arni de acuaporina 1 para tratamiento de afecciones relacionadas con pio
AR111697A2 (es) Composición oftálmica para el tratamiento de las alergias oculares
ATE511506T1 (de) Thiopen-derivate als wirkstoffe gegen okulare hypotonie

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170505